Best Anthracycline Topoisomerase Inhibitor for leukemia, myelogenous, chronic, bcr-abl positive
2 Anthracycline Topoisomerase Inhibitor drugs indicated for leukemia, myelogenous, chronic, bcr-abl positive, ranked by our independent rating. The current highest-rated is idarubicin hydrochloride. Compare them with all treatments for leukemia, myelogenous, chronic, bcr-abl positive or the full Anthracycline Topoisomerase Inhibitor class. Not medical advice — always consult a professional.
Top anthracycline topoisomerase inhibitor for leukemia, myelogenous, chronic, bcr-abl positive: 1. Idarubicin Hydrochloride · 2. Idamycin Pfs
| # | Drug | Rating | Type | Typical price | |
|---|---|---|---|---|---|
| 1 | Idarubicin Hydrochloride | 70/100 | Prescription | — | View → |
| 2 | Idamycin Pfs | 56/100 | Prescription | — | View → |
Full ranking · 2 drugs
Frequently asked
- What is the best anthracycline topoisomerase inhibitor for leukemia, myelogenous, chronic, bcr-abl positive?
- By our independent rating, idarubicin hydrochloride currently ranks highest among Anthracycline Topoisomerase Inhibitor drugs used for leukemia, myelogenous, chronic, bcr-abl positive. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.
- Which anthracycline topoisomerase inhibitor drugs treat leukemia, myelogenous, chronic, bcr-abl positive?
- pharmaranks lists 2 Anthracycline Topoisomerase Inhibitor products indicated for leukemia, myelogenous, chronic, bcr-abl positive, per FDA drug-label data — each independently rated and ranked above.
- How are these ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
